Editorials
Relapsed acute myeloblastic leukemia: first pediatric randomized study
Abstract
The current cure rate achieves 80% of long-term survival in childhood acute lymphoblastic leukemia (ALL) and only 50-60% in acute myeloblastic leukemia (AML) (1). However, in patients who relapse following treatment of AML, the odds are not as far in their favor, and the probability of overall survival is 16-34% (2,3).